These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16964269)

  • 1. Poor oral nutrition after allogeneic stem cell transplantation correlates significantly with severe graft-versus-host disease.
    Mattsson J; Westin S; Edlund S; Remberger M
    Bone Marrow Transplant; 2006 Nov; 38(9):629-33. PubMed ID: 16964269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition.
    Svahn BM; Remberger M; Heijbel M; Martell E; Wikström M; Eriksson B; Milovsavljevic R; Mattsson J; Ringdén O
    Transplantation; 2008 Apr; 85(7):1000-7. PubMed ID: 18408581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
    Izumi N; Furukawa T; Sato N; Okazuka K; Tsukada N; Abe T; Yano T; Kurasaki T; Masuko M; Toba K; Takahashi M; Aizawa Y
    Bone Marrow Transplant; 2007 Nov; 40(9):875-80. PubMed ID: 17724440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Imataki O; Nakatani S; Hasegawa T; Kondo M; Ichihashi K; Araki M; Ishida T; Kim SW; Mori S; Fukuda T; Tobinai K; Tanosaki R; Makimoto A; Takaue Y
    Am J Hematol; 2006 Oct; 81(10):747-52. PubMed ID: 16865687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular monitoring of T-cell chimerism early after allogeneic stem cell transplantation may predict the occurrence of acute GVHD grades II-IV.
    Jaksch M; Uzunel M; Remberger M; Sundberg B; Mattsson J
    Clin Transplant; 2005 Jun; 19(3):346-9. PubMed ID: 15877796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
    Mori T; Aisa Y; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Yamane A; Ikeda Y; Okamoto S
    Transplant Proc; 2007 Jun; 39(5):1615-9. PubMed ID: 17580201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
    Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
    Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies.
    Ozdemir E; Saliba RM; Champlin RE; Couriel DR; Giralt SA; de Lima M; Khouri IF; Hosing C; Kornblau SM; Anderlini P; Shpall EJ; Qazilbash MH; Molldrem JJ; Chemaly RF; Komanduri KV
    Bone Marrow Transplant; 2007 Jul; 40(2):125-36. PubMed ID: 17530009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The graft content of donor T cells expressing gamma delta TCR+ and CD4+foxp3+ predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors.
    Pabst C; Schirutschke H; Ehninger G; Bornhäuser M; Platzbecker U
    Clin Cancer Res; 2007 May; 13(10):2916-22. PubMed ID: 17504991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades.
    Svahn BM; Ringdén O; Remberger M
    Transplantation; 2006 Jun; 81(11):1600-3. PubMed ID: 16770251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
    Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor (VEGF) is associated with reduced severity of acute graft-versus-host disease and nonrelapse mortality after allogeneic stem cell transplantation.
    Min CK; Kim SY; Lee MJ; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Kim CC; Cho CS
    Bone Marrow Transplant; 2006 Jul; 38(2):149-56. PubMed ID: 16751784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation.
    Aisa Y; Mori T; Nakazato T; Shimizu T; Yamazaki R; Ikeda Y; Okamoto S
    Transpl Int; 2007 Sep; 20(9):761-70. PubMed ID: 17578455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.